Japan Adds iPS Cell-Derived Parkinson’s Treatment to National Health Insurance at ¥50 Million per Patient

An advisory panel to the health minister approved Sumitomo Pharma’s Parkinson’s disease treatment Amchepry on May 13, 2026. 3 million ($350,600) per patient, for coverage under Japan's national healthcare program. The approval marks the first commercialized medical product in the world derived from iPS cells.

Those cells are created by reprogramming adult cells such as blood or skin cells into a versatile state capable of developing into different tissue types, The Japan Times reported. IPS cells for Amchepry were cultured by Sumitomo Pharma. Insurance coverage for the treatment will begin on May 20, 2026.

Treatment with Amchepry is expected to be available this fall. 3 million, equivalent to $350,600 per patient, reflects the pioneering nature of the iPS cell technology involved. The decision advances years of research into induced pluripotent stem cells, which can be coaxed to replace damaged tissue in conditions such as Parkinson’s.

By winning national healthcare coverage, Amchepry moves from experimental status into routine clinical reach for patients across Japan beginning this fall.